TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
January 29, 2024 08:30 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
January 22, 2024 16:45 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics closes public offering
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
January 18, 2024 13:27 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
January 12, 2024 16:05 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses, Increased Focus on Planned Phase 1 Clinical Trial; Retirement of CEO
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
January 11, 2024 08:00 ET
|
TransCode Therapeutics, Inc.
TransCode Announces Reverse Stock Split
TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives
January 04, 2024 08:05 ET
|
TransCode Therapeutics, Inc.
An Open Letter to Shareholders of TransCode Therapeutics, Inc.
TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
December 12, 2023 08:30 ET
|
TransCode Therapeutics, Inc.
BOSTON, Dec. 12, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported...
TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
December 05, 2023 09:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, Dec. 05, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, will present...
TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
December 04, 2023 16:10 ET
|
TransCode Therapeutics, Inc.
BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
November 30, 2023 14:53 ET
|
TransCode Therapeutics, Inc.
BOSTON, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...